Doing well in very lousy marketsInvesting in biotechs is a very risky business. The reason investors do it is the potential rewards are enormous. I like the fact that Sernova management is taking a steady measured approach to moving the science and the business along. It gives me a sense of comfort that our stock price represents value as much as can be measured in this volatile sector. I know some of us would like things to move along much more quickly. For management to speed things up risks them crossing the fine line from promotion to hype which adds price volatility both up and down and confusion as to where the value is for me. And for me this is key especially with the markets overvalued and currently correcting. Sernova has been obviously busy on many fronts and has even brought Frank Holler in to operations to help out. I am a happy camper so far.